![Nigel McCracken](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nigel McCracken
Chief Operating Officer at
VIRAX BIOLABS GROUP LIMITED
Net worth: 7 447 $ as of 30/06/2026
Profile
Nigel McCracken currently works at Virax Biolabs Group Ltd., as Chief Operating Officer & Director.
Dr. McCracken also formerly worked at Debiopharm International SA, as Executive Director & VP-Translational Medicine from 2014 to 2019, NuCana Plc, as COO, Senior VP-Discovery & Early Development, and BerGenBio ASA, as Chief Scientific Officer from 2021 to 2023.
Dr. McCracken received his undergraduate degree from the University of Strathclyde and graduate degree from King's College London.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 02/07/2026 | 2,533 ( 0.32% ) | 7 447 $ | 30/06/2026 |
Nigel McCracken active positions
| Companies | Position | Start |
|---|---|---|
| VIRAX BIOLABS GROUP LIMITED | Chief Operating Officer | 01/09/2023 |
Former positions of Nigel McCracken
| Companies | Position | End |
|---|---|---|
| ONCOINVENT ASA | Chief Tech/Sci/R&D Officer | 01/09/2023 |
Debiopharm International SA
 Debiopharm International SA BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops drugs to cure cancer and infectious diseases | Director/Board Member | 01/04/2019 |
| NUCANA PLC | Chief Operating Officer | - |
Training of Nigel McCracken
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
5
1st degree connections
6
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Debiopharm International SA
Debiopharm International SA BiotechnologyHealth Technology Operates as a biopharmaceutical company which develops drugs to cure cancer and infectious diseases | Health Technology |
University of Strathclyde
 University of Strathclyde Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
King's College London
 King's College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BerGenBio ASA
 BerGenBio ASA Pharmaceuticals: MajorHealth Technology Develops drugs for aggressive, drug resistant cancers | Health Technology |
NuCana Plc
 NuCana Plc BiotechnologyHealth Technology Develops and commercializes novel anti-cancer medicines | Health Technology |
Virax Biolabs Group Ltd.
 Virax Biolabs Group Ltd. Financial ConglomeratesFinance Develops and distributes immunology software, platform and medical devices | Finance |
- Stock Market
- Insiders
- Nigel McCracken
